The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Introduction: A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA. Areas covered: Observational cohort, randomized controlled trials and case-controlled studies were included. The systematic literature search was conducted in PubMed, Wiley/Embase, Cochrane, Web of Science and clinicaltrials.gov (up to 2017). Two authors assessed abstracts for inclusion and methodological quality was assessed by one reviewer. Expert opinion: RA patients have a clinically relevant increased risk of developing CHF needing further attention. However, we found a lack of high quality studies. Future studies should focus on distinguishing the effect of myocardial inflammation reduction versus antibody-specific myocardial cellular effects of bDMARDs to improve the understanding of the effects of bDMARDs in RA patients and the relation with the development of CHF.
Original languageEnglish
Pages (from-to)585-594
JournalExpert Opinion on Biological Therapy
Volume18
Issue number5
DOIs
Publication statusPublished - 2018

Cite this

@article{624914482bcc468d8fdb254bd1b606d8,
title = "The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review",
abstract = "Introduction: A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA. Areas covered: Observational cohort, randomized controlled trials and case-controlled studies were included. The systematic literature search was conducted in PubMed, Wiley/Embase, Cochrane, Web of Science and clinicaltrials.gov (up to 2017). Two authors assessed abstracts for inclusion and methodological quality was assessed by one reviewer. Expert opinion: RA patients have a clinically relevant increased risk of developing CHF needing further attention. However, we found a lack of high quality studies. Future studies should focus on distinguishing the effect of myocardial inflammation reduction versus antibody-specific myocardial cellular effects of bDMARDs to improve the understanding of the effects of bDMARDs in RA patients and the relation with the development of CHF.",
author = "Milad Baniaamam and Paulus, {Walter J.} and Blanken, {Annelies B.} and Nurmohamed, {Michael T.}",
year = "2018",
doi = "10.1080/14712598.2018.1462794",
language = "English",
volume = "18",
pages = "585--594",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review. / Baniaamam, Milad; Paulus, Walter J.; Blanken, Annelies B.; Nurmohamed, Michael T.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 5, 2018, p. 585-594.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review

AU - Baniaamam, Milad

AU - Paulus, Walter J.

AU - Blanken, Annelies B.

AU - Nurmohamed, Michael T.

PY - 2018

Y1 - 2018

N2 - Introduction: A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA. Areas covered: Observational cohort, randomized controlled trials and case-controlled studies were included. The systematic literature search was conducted in PubMed, Wiley/Embase, Cochrane, Web of Science and clinicaltrials.gov (up to 2017). Two authors assessed abstracts for inclusion and methodological quality was assessed by one reviewer. Expert opinion: RA patients have a clinically relevant increased risk of developing CHF needing further attention. However, we found a lack of high quality studies. Future studies should focus on distinguishing the effect of myocardial inflammation reduction versus antibody-specific myocardial cellular effects of bDMARDs to improve the understanding of the effects of bDMARDs in RA patients and the relation with the development of CHF.

AB - Introduction: A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA. Areas covered: Observational cohort, randomized controlled trials and case-controlled studies were included. The systematic literature search was conducted in PubMed, Wiley/Embase, Cochrane, Web of Science and clinicaltrials.gov (up to 2017). Two authors assessed abstracts for inclusion and methodological quality was assessed by one reviewer. Expert opinion: RA patients have a clinically relevant increased risk of developing CHF needing further attention. However, we found a lack of high quality studies. Future studies should focus on distinguishing the effect of myocardial inflammation reduction versus antibody-specific myocardial cellular effects of bDMARDs to improve the understanding of the effects of bDMARDs in RA patients and the relation with the development of CHF.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047303195&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29623726

U2 - 10.1080/14712598.2018.1462794

DO - 10.1080/14712598.2018.1462794

M3 - Review article

VL - 18

SP - 585

EP - 594

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -